Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 3
1984 5
1985 30
1986 77
1987 92
1988 130
1989 167
1990 200
1991 182
1992 277
1993 302
1994 344
1995 347
1996 352
1997 329
1998 317
1999 337
2000 323
2001 361
2002 347
2003 319
2004 378
2005 384
2006 352
2007 318
2008 356
2009 364
2010 388
2011 395
2012 425
2013 421
2014 397
2015 455
2016 439
2017 410
2018 356
2019 389
2020 408
2021 420
2022 348
2023 29
Text availability
Article attribute
Article type
Publication date

Search Results

11,416 results
Results by year
Filters applied: . Clear all
Page 1
Evolution of Neuroendocrine Tumor Therapy.
O'Dorisio TM, Harris AG, O'Dorisio MS. O'Dorisio TM, et al. Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002. Surg Oncol Clin N Am. 2020. PMID: 32151353 Free PMC article. Review.
ANNIVERSARY REVIEW: Octreotide, 40 years later.
Lamberts SWJ, Hofland LJ. Lamberts SWJ, et al. Eur J Endocrinol. 2019 Nov;181(5):R173-R183. doi: 10.1530/EJE-19-0074. Eur J Endocrinol. 2019. PMID: 31398712 Review.
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. ...This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the p
Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. ...This
Octreotide.
Stajich GV, Ashworth L. Stajich GV, et al. Neonatal Netw. 2006 Sep-Oct;25(5):365-9. doi: 10.1891/0730-0832.25.5.365. Neonatal Netw. 2006. PMID: 16989134 Review.
Prompt institution of octreotide therapy after surgery in patients with significant drainage or the formation of chyle may reduce the expense and morbidity associated with a prolonged hospital stay. Given the individual variability in patient response to octreotide
Prompt institution of octreotide therapy after surgery in patients with significant drainage or the formation of chyle may reduce the …
Octreotide in hyperinsulinism.
Barrons RW. Barrons RW. Ann Pharmacother. 1997 Feb;31(2):239-41. doi: 10.1177/106002809703100217. Ann Pharmacother. 1997. PMID: 9034427 Review.
Among the few case reports in adults with benign or malignant insulinoma, octreotide can significantly raise blood glucose concentrations. In long-term follow-up, octreotide has alleviated or reduced the frequency of hypoglycemic episodes for periods of 5 months to …
Among the few case reports in adults with benign or malignant insulinoma, octreotide can significantly raise blood glucose concentrat …
Octreotide.
Murphy E, Prommer EE, Mihalyo M, Wilcock A. Murphy E, et al. J Pain Symptom Manage. 2010 Jul;40(1):142-8. doi: 10.1016/j.jpainsymman.2010.05.002. J Pain Symptom Manage. 2010. PMID: 21634046 Free article. Review. No abstract available.
Octreotide.
[No authors listed] [No authors listed] Lancet. 1989 Sep 2;2(8662):541-2. Lancet. 1989. PMID: 2570240 No abstract available.
Octreotide for the treatment of chylothorax in neonates.
Das A, Shah PS. Das A, et al. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD006388. doi: 10.1002/14651858.CD006388.pub2. Cochrane Database Syst Rev. 2010. PMID: 20824848 Review.
Nineteen case reports of 20 neonates with chylothorax in whom octreotide was used either subcutaneously or intravenously were identified. ...A prospective registry of chylothorax patients and a subsequent multicenter randomised controlled trial are needed to assess the saf …
Nineteen case reports of 20 neonates with chylothorax in whom octreotide was used either subcutaneously or intravenously were identif …
Octreotide and chylothorax.
Kalomenidis I. Kalomenidis I. Curr Opin Pulm Med. 2006 Jul;12(4):264-7. doi: 10.1097/01.mcp.0000230629.73139.26. Curr Opin Pulm Med. 2006. PMID: 16825878 Review.
The property of somatostatin and octreotide to induce leak closure is attributed to a decelerating effect on lymph flow, although their exact mechanism of action is not well defined. ...Treatment failure has been also reported, however. SUMMARY: Accumulating evidence sugge …
The property of somatostatin and octreotide to induce leak closure is attributed to a decelerating effect on lymph flow, although the …
Octreotide for the treatment of sulfonylurea poisoning.
Glatstein M, Scolnik D, Bentur Y. Glatstein M, et al. Clin Toxicol (Phila). 2012 Nov;50(9):795-804. doi: 10.3109/15563650.2012.734626. Epub 2012 Oct 10. Clin Toxicol (Phila). 2012. PMID: 23046209 Review.
IV dextrose (10-25%) was administered before and after octreotide therapy. Octreotide was given after failure to correct hypoglycemia with IV dextrose in doses of 0.51-2 mug/kg IV or SC; two also required an IV octreotide infusion. ...Maintenance doses of …
IV dextrose (10-25%) was administered before and after octreotide therapy. Octreotide was given after failure to correct hypog …
[Octreotide].
Herzig S, Mönig H. Herzig S, et al. Dtsch Med Wochenschr. 1995 Jul 28;120(30):1051-2. doi: 10.1055/s-0029-1234210. Dtsch Med Wochenschr. 1995. PMID: 7628318 German. No abstract available.
11,416 results
You have reached the last available page of results. Please see the User Guide for more information.